Physician profile
James M Bachstein
NPI 1104802271
$919.36
in general payments reported to CMS, 2019-2025
23 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.99 · 2021: $20.27 · 2022: $32.60 · 2023: $117 · 2024: $595 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $142.38 | 2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $101.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Aimmune Therapeutics, INC. | $75.47 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $57.67 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $54.93 | 2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $44.65 | 2024 | Veozah |
| Boston Scientific Corporation | $41.28 | 2024 | Wavewriter Alpha Prime 16 |
| Qol Medical, LLC | $40.70 | 2024-2025 | Sucraid, Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.93 | 2023-2024 | Ofev |
| Cequr Corporation | $32.32 | 2024 | Cequr Simplicity |
| Ardelyx, INC. | $29.42 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $29.35 | 2025 | Rezdiffra |
| Abbvie INC. | $28.33 | 2022-2023 | Mavyret |
| Jazz Pharmaceuticals INC. | $26.22 | 2024 | |
| Axsome Therapeutics, INC. | $23.25 | 2024 | Sunosi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.01 | 2023 | Aptima |
| Merck Sharp & Dohme LLC | $21.81 | 2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $21.48 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $20.27 | 2021 | |
| Pfizer INC. | $18.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.09 | 2023 | Xifaxan |
| Janssen Biotech, INC. | $17.41 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $14.98 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bachstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.